MetaVia Inc.
MTVA · XNASCIK 1638287fmd_0B5PX0DBJ4F29GR488SD0PW8KBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net interest income | 0 | (0) | (0) | (0) | 0 | 0 | – | 0 | 1 | 1 |
| Research and development | 9 | 23 | 5 | 5 | 5 | 7 | 3 | 9 | 22 | 7 |
| Total operating expenses | – | – | – | – | – | – | – | – | 29 | 14 |
| Operating income | (15) | (33) | (15) | (20) | (30) | (15) | (20) | (16) | (29) | (14) |
| Other non-operating income (expense) | (0) | (0) | (0) | – | (0) | 0 | 6 | 3 | 1 | 1 |
| Income before taxes | (15) | (33) | (16) | (21) | (30) | (15) | (14) | (12) | (28) | (13) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (15) | (33) | (16) | (21) | (30) | (15) | (14) | (12) | (28) | (13) |
| Net income | (15) | (33) | (16) | (21) | (30) | (15) | (14) | (12) | (28) | (13) |
| Net income to common shareholders | (15) | (33) | (24) | – | – | – | – | – | – | – |